MX2021013386A - Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas. - Google Patents
Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas.Info
- Publication number
- MX2021013386A MX2021013386A MX2021013386A MX2021013386A MX2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A MX 2021013386 A MX2021013386 A MX 2021013386A
- Authority
- MX
- Mexico
- Prior art keywords
- indigo
- compositions
- methods
- derivative
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843184P | 2019-05-03 | 2019-05-03 | |
| PCT/US2020/031174 WO2020227151A1 (en) | 2019-05-03 | 2020-05-01 | Compositions comprising indigo and/or an indigo derivative and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013386A true MX2021013386A (es) | 2022-03-22 |
Family
ID=70775588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013386A MX2021013386A (es) | 2019-05-03 | 2020-05-01 | Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20200345645A1 (enExample) |
| EP (1) | EP3962458A1 (enExample) |
| JP (1) | JP2022531012A (enExample) |
| KR (1) | KR20220044435A (enExample) |
| CN (1) | CN114340600A (enExample) |
| AU (1) | AU2020269379A1 (enExample) |
| CA (1) | CA3136081A1 (enExample) |
| MX (1) | MX2021013386A (enExample) |
| TW (1) | TW202106296A (enExample) |
| WO (1) | WO2020227151A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| KR20240152820A (ko) | 2021-11-30 | 2024-10-22 | 엔도퀘스트 로보틱스 인코포레이티드 | 로봇 제어 의료 기기용 힘 전달 시스템 |
| WO2023170714A1 (en) * | 2022-03-10 | 2023-09-14 | Joy Vadakkan Thomas | A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases |
| JP2025532421A (ja) * | 2022-10-10 | 2025-09-29 | 上海澤徳曼医薬科技有限公司 | 潰瘍を予防及び又は治療するためのスチルベン誘導体の使用 |
| WO2025008784A1 (en) * | 2023-07-04 | 2025-01-09 | Glenmark Life Sciences Limited | Solid dispersions of tapinarof and a process for the preparation thereof |
| CN121337758A (zh) * | 2025-11-26 | 2026-01-16 | 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) | 一种可降解的肠道药物靶向释放胶囊及制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| JP2013103899A (ja) * | 2011-11-11 | 2013-05-30 | Fuji Chem Ind Co Ltd | 難溶性薬物の新規な固体分散体 |
| EP2863897B1 (en) * | 2012-06-21 | 2019-06-19 | Phosphorex Inc. | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
| TWI615157B (zh) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
| JP2017500343A (ja) * | 2013-12-20 | 2017-01-05 | フォスフォレックス，インコーポレーテッド | インジルビン固体分散体組成物 |
| BR112017021190B1 (pt) | 2015-04-09 | 2021-12-21 | Galderma Sa. | Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis |
| BR112018071370A2 (pt) * | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de mesalazina |
| JP7325753B2 (ja) * | 2018-01-18 | 2023-08-15 | 慶應義塾 | 潰瘍性大腸炎治療カプセル剤 |
-
2020
- 2020-05-01 US US16/865,183 patent/US20200345645A1/en not_active Abandoned
- 2020-05-01 CN CN202080042143.2A patent/CN114340600A/zh active Pending
- 2020-05-01 EP EP20727107.3A patent/EP3962458A1/en not_active Withdrawn
- 2020-05-01 TW TW109114724A patent/TW202106296A/zh unknown
- 2020-05-01 JP JP2021565743A patent/JP2022531012A/ja active Pending
- 2020-05-01 WO PCT/US2020/031174 patent/WO2020227151A1/en not_active Ceased
- 2020-05-01 AU AU2020269379A patent/AU2020269379A1/en not_active Abandoned
- 2020-05-01 CA CA3136081A patent/CA3136081A1/en active Pending
- 2020-05-01 KR KR1020217039676A patent/KR20220044435A/ko not_active Withdrawn
- 2020-05-01 MX MX2021013386A patent/MX2021013386A/es unknown
-
2022
- 2022-04-22 US US17/727,510 patent/US20220249382A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/053,798 patent/US20250255820A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202106296A (zh) | 2021-02-16 |
| US20200345645A1 (en) | 2020-11-05 |
| CA3136081A1 (en) | 2020-11-12 |
| US20220249382A1 (en) | 2022-08-11 |
| CN114340600A (zh) | 2022-04-12 |
| EP3962458A1 (en) | 2022-03-09 |
| AU2020269379A1 (en) | 2021-12-02 |
| KR20220044435A (ko) | 2022-04-08 |
| WO2020227151A1 (en) | 2020-11-12 |
| US20250255820A1 (en) | 2025-08-14 |
| JP2022531012A (ja) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013386A (es) | Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas. | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| DOP2022000115A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| ZA201906822B (en) | Indole ahr inhibitors and uses thereof | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| BR112021024830A2 (pt) | Vesículas extracelulares microbianas processadas | |
| BR112019023290A2 (pt) | Tienopiridinas e benzotiofenos úteis como inibidores de irak4 | |
| CL2015003569A1 (es) | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct | |
| MX390083B (es) | Formulaciones de (r)-2-amino-3-fenilpropil carbamato. | |
| CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| MX2025010681A (es) | Formulaciones transdermicas | |
| MX2018009633A (es) | Inhibidor de indoleamina-2,3-dioxigenasa (ido). | |
| EA201892200A1 (ru) | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге | |
| MX2022014457A (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| CO2020001325A2 (es) | Combinaciones herbicidas sinérgicas | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| EA201892500A1 (ru) | Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции | |
| CL2019002840A1 (es) | Formas cristalinas de (s)-afoxolaner. |